Aquestive Therapeutics (AQST) Projected to Release Quarterly Earnings on Tuesday

Posted by Brian Himes on Aug 4th, 2026

Aquestive Therapeutics (NASDAQ:AQST – Get Free Report) is anticipated to post its Q2 2026 results after the market closes on Tuesday, August 11th. Analysts expect the company to post earnings of ($0.10) per share and revenue of $11.42 million for the quarter. Investors can check the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Wednesday, August 12, 2026 at 8:00 AM ET.

Aquestive Therapeutics (NASDAQ:AQST – Get Free Report) last issued its earnings results on Wednesday, May 13th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.07. The firm had revenue of $14.45 million during the quarter, compared to analyst estimates of $10.90 million. On average, analysts expect Aquestive Therapeutics to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Aquestive Therapeutics Price Performance

NASDAQ AQST traded down $0.07 during trading on Tuesday, reaching $3.73. 440,199 shares of the company’s stock were exchanged, compared to its average volume of 2,985,845. The business has a 50 day moving average price of $4.13 and a 200-day moving average price of $4.04. The stock has a market capitalization of $467.38 million, a P/E ratio of -6.11 and a beta of 1.49. Aquestive Therapeutics has a fifty-two week low of $2.93 and a fifty-two week high of $7.55.

Insiders Place Their Bets

In other Aquestive Therapeutics news, Director Julie Krop sold 25,000 shares of the business’s stock in a transaction on Tuesday, June 23rd. The shares were sold at an average price of $5.02, for a total transaction of $125,500.00. Following the sale, the director owned 25,000 shares of the company’s stock, valued at approximately $125,500. The trade was a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Barber sold 8,257 shares of the company’s stock in a transaction on Friday, May 15th. The stock was sold at an average price of $4.29, for a total transaction of $35,422.53. Following the transaction, the chief executive officer owned 660,574 shares of the company’s stock, valued at $2,833,862.46. This trade represents a 1.23% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 6.81% of the company’s stock.

Hedge Funds Weigh In On Aquestive Therapeutics

Large investors have recently bought and sold shares of the company. Victory Capital Management Inc. increased its position in Aquestive Therapeutics by 17.0% during the 3rd quarter. Victory Capital Management Inc. now owns 12,794 shares of the company’s stock valued at $72,000 after purchasing an additional 1,862 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Aquestive Therapeutics by 6.0% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 47,098 shares of the company’s stock worth $156,000 after purchasing an additional 2,649 shares during the period. Informed Momentum Co LLC lifted its position in shares of Aquestive Therapeutics by 1.8% in the 4th quarter. Informed Momentum Co LLC now owns 155,053 shares of the company’s stock worth $1,002,000 after purchasing an additional 2,721 shares during the period. Stifel Financial Corp lifted its position in shares of Aquestive Therapeutics by 0.9% in the 4th quarter. Stifel Financial Corp now owns 369,728 shares of the company’s stock worth $2,388,000 after purchasing an additional 3,300 shares during the period. Finally, AQR Capital Management LLC boosted its stake in shares of Aquestive Therapeutics by 6.8% in the 4th quarter. AQR Capital Management LLC now owns 61,709 shares of the company’s stock valued at $399,000 after purchasing an additional 3,934 shares during the last quarter. 32.45% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the stock. Wall Street Zen upgraded shares of Aquestive Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. Oppenheimer initiated coverage on Aquestive Therapeutics in a research report on Friday, April 24th. They issued an “outperform” rating and a $8.00 target price on the stock. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Aquestive Therapeutics in a research note on Friday, July 17th. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Aquestive Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $8.50.

Read Our Latest Stock Analysis on Aquestive Therapeutics

About Aquestive Therapeutics

(Get Free Report)

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.

The company’s lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.